01 siRNA Therapeutics R&D Platform
AI x siRNA
Innovative Integration
Generative AI & First-Principles
Redefining Sequence Design
02
Technology Engine
Kodexia™
AI-Centric
siRNA Drug Discovery Platform
siRNA therapeutics leverage the endogenous RNA interference (RNAi) pathway to precisely target disease-associated mRNA upstream of protein expression, enabling long-lasting and safe disease modulation.
Kodexia™ is a pioneering siRNA drug development platform that integrates generative AI with first-principles science through a closed-loop dry-wet lab system. The platform is powered by data, algorithms, and high-throughput experimentation, while incorporating mechanistic knowledge of siRNA silencing, RNA thermodynamics, and structural properties to enable practical, AI-driven siRNA drug discovery.
Kodexia™ integrates AI throughout the entire siRNA R&D workflow, spanning target-site identification, sequence design & modification recommendation, experimental validation, delivery optimization, and IP-informed design. This enables the rapid optimization of critical objectives, including safety, extended durability, superior in vitro to in vivo translation, and freedom to operate (FTO), significantly shortening R&D timelines and demonstrating the capability to generate highly competitive siRNA candidates.
Kodexia™ is a pioneering siRNA drug development platform that integrates generative AI with first-principles science through a closed-loop dry-wet lab system. The platform is powered by data, algorithms, and high-throughput experimentation, while incorporating mechanistic knowledge of siRNA silencing, RNA thermodynamics, and structural properties to enable practical, AI-driven siRNA drug discovery.
Kodexia™ integrates AI throughout the entire siRNA R&D workflow, spanning target-site identification, sequence design & modification recommendation, experimental validation, delivery optimization, and IP-informed design. This enables the rapid optimization of critical objectives, including safety, extended durability, superior in vitro to in vivo translation, and freedom to operate (FTO), significantly shortening R&D timelines and demonstrating the capability to generate highly competitive siRNA candidates.
03
Platform Advantages
Kodexia™
Core Platform Advantages
Integrated Sequence and Modification Design - Moving Beyond Empirical Design for Multi-Objective Optimization
Kodexia™ pioneers the integrated optimization of siRNA sequence design and chemical modification. By moving beyond empirical design rules and navigating patent constraints from the outset, the platform enhances molecular potency, durability, and safety from the earliest stages of molecular design.
Kodexia™ pioneers the integrated optimization of siRNA sequence design and chemical modification. By moving beyond empirical design rules and navigating patent constraints from the outset, the platform enhances molecular potency, durability, and safety from the earliest stages of molecular design.
High-Throughput "Closed-Loop Dry-Wet Lab" Iteration - Building Defensible Advantages in Data and Algorithms
Kodexia™ tightly integrates AI-driven molecular design with high-throughput automated wet-lab experimentation. AI-designed candidates are rapidly validated, with experimental data continuously fed back into AI models for iterative refinement. Powered by XtalPi’s proprietary AI platform, Kodexia™ improves molecular design efficiency by 2- to 3-fold compared with conventional R&D approaches.
Kodexia™ tightly integrates AI-driven molecular design with high-throughput automated wet-lab experimentation. AI-designed candidates are rapidly validated, with experimental data continuously fed back into AI models for iterative refinement. Powered by XtalPi’s proprietary AI platform, Kodexia™ improves molecular design efficiency by 2- to 3-fold compared with conventional R&D approaches.
In Vivo Efficacy Prediction
Moving beyond in vivo potency, Kodexia™ features predictive models for in vivo efficacy. By evaluating the expected in vivo performance of candidate molecules early in discovery, the platform helps bridge the translational gap between in in vitro and in vivo outcomes, significantly increasing the likelihood that promising candidates translate into strong in vivo performance.
Moving beyond in vivo potency, Kodexia™ features predictive models for in vivo efficacy. By evaluating the expected in vivo performance of candidate molecules early in discovery, the platform helps bridge the translational gap between in in vitro and in vivo outcomes, significantly increasing the likelihood that promising candidates translate into strong in vivo performance.
Dual-Targeting siRNA Design and Extrahepatic Delivery
To address complex diseases, Kodexia™ continues to expand the therapeutic space of siRNA. The platform co-optimizes the dual-targeting siRNAs as integrated entities, addressing the limitations of single-target interventions. In parallel, Kodexia™ is building a multi-modal delivery toolkit spanning antibody conjugates, peptide conjugates, small molecule conjugates and lipid nanoparticles (LNPs), supporting the expansion of siRNA therapeutics into a broader range of indications.
To address complex diseases, Kodexia™ continues to expand the therapeutic space of siRNA. The platform co-optimizes the dual-targeting siRNAs as integrated entities, addressing the limitations of single-target interventions. In parallel, Kodexia™ is building a multi-modal delivery toolkit spanning antibody conjugates, peptide conjugates, small molecule conjugates and lipid nanoparticles (LNPs), supporting the expansion of siRNA therapeutics into a broader range of indications.
04
Pipeline Progress
Continuously Expanding Technical Boundaries Focusing on Nucleic Acid Therapeutics Development
Accelerate discovery with vast diversity and precision screening
Building on deep expertise in siRNA therapeutics, Kodexia™ currently supports six differentiated programs, more than half of which have completed in vivo evaluation, validating the potential to become First-in-Class (FIC) or Best-in-Class (BIC) therapeutics across metabolic, renal, respiratory, and CNS diseases.
siRNA is one of the most clinically advanced and promising therapeutic modalities in the oligonucleotide field. While continuing to deepen our expertise and capabilities in siRNA, we are simultaneously developing AI prediction models for other oligonucleotide modalities, such as ASOs, to continuously expand the technological scope of our platform.
siRNA is one of the most clinically advanced and promising therapeutic modalities in the oligonucleotide field. While continuing to deepen our expertise and capabilities in siRNA, we are simultaneously developing AI prediction models for other oligonucleotide modalities, such as ASOs, to continuously expand the technological scope of our platform.
Your next success starts here
Harness the power of AI & Automation to discover new life-changing drugs, faster and more efficiently.